Flashcards in 9.15.16 Lecture Deck (33):
Describe the typical gain-of-function cancer mutation.
Single overactivity mutation event that creates an oncogene to promote cell transformation; acts in a dominant manner.
Describe the typical loss-of-function cancer mutation.
Underactivity mutation; need mutations in both copies of a tumor suppressor gene, promoting transformation; acts in a recessive manner.
Genes mutated in cancer can be made overactive in many ways. Describe these.
1. Deletion or point mutation in coding sequence leads to hyperactive protein made in normal amounts.
2. Regulatory mutation leads to normal protein greatly overproduced.
3. Gene amplification leads to normal protein greatly overproduced.
4. Chromosome rearrangement in a nearby regulatory DNA sequence causes normal protein to be overproduced.
5. Chromosome rearrangement via fusion to actively transcribed gene produces hyperactive fusion protein.
Mutation of ___ receptor can make the receptor active even in the absence of its ligand, and consequently ongogenic.
Epidermal growth factor
Describe the outcomes of a normal, healthy individual, an individual with hereditary retinoblastoma, and an inidividual with nonhereditary retinoblastoma.
Normal individual may have occasional cell inactivation of 1 of 2 good Rb genes, no tumor is produced. Individual with hereditary retinoblastoma inherits mutant Rb gene. Occasional cell inactivates its only good Rb gene, leading to excessive cell proliferation and a retinoblastoma. This individual typically has multiple tumors in both eyes. The individual with nonhereditary retinoblastoma has an occasional cell inactivate 1 of 2 good Rb gene. This happens again to the remaining good Rb gene, leading to excessive cell proliferation and retinoblastoma. 1/30,000 people develop 1 tumor in 1 eye.
Both genetic and epigenetic mechanisms can inactivate tumor suppressor genes. Describe the genetic mechanisms by which this may occur.
Nondisjunction leading to chromosome loss, chromosome loss followed by duplication, mitotic recombination, gene conversion during recombination, deletion, and point mutation.
Describe the epigenetic mechanisms that can inactivate tumor suppressor genes.
DNA methylation and packaging the gene into condensed chromatin.
Oncogenes typically involve ___ mutations. Tumor suppressor genes typically involve ___ or ___ mutations that abort protein synthesis by creating stop codons.
Missense; truncating; missense.
Many caners have disrupted genomes; this can be represented by ___ plots, which show what three things?
Circos; highly amplified regions, intrachromosomal rearrangements, interchromosomal rearrangements
Describe the difference between driver and passenger mutations.
Driver mutations (~10/cancer) are seen at a higher frequency, may be present in all cells of a given tumor; causal factors. Passenger mutations (~300/cancer) are more sporadic and many not be present in all tumor cells due to heterogeneity; phenotypic factor.
Mutations in the ___ pathway drive cancer cells to grow. Most normal cells need signals (___) that drive cell-cycle progression and signals (___) that drive cell growth.
PI3K/Akt/TOR; mitogens; growth factors
Describe the PI3K/Akt/TOR pathway.
Glucose binds to a glucose transporter. Glucose transport increases, leading to an increase in glycolysis. This increases pyruvate, which increases the TCA cycle in the mitochondria. This increases release of citrate into the cytosol, leading to the formation of acetyl CoA. This leads to lipid synthesis, which leads to membrane biosynthesis for cell growth. In addition, growth factors bind, activating receptor tyrosine kinases. This activates the PI-3 kinase, which activates Akt, which activates mTOR, which increases protein synthesis and increases glycolysis.
The PI3K/Akt/TOR pathway becomes abnormally activated ___ in tumor progression.
___ occurs as cells form microcolonies.
EMT transition of transformed cells is induced by extracellular ___ and ___, which originate from where?
TGFbeta; Wnt; activation by proteases of pro-TGFbeta in ECM, secretion of TGFbeta/Wnt from untransformed cells or by secretion from tumor cells themselves.
Cancer stem cells sustain ___ and the characteristics overlap with mesenchymal metastic cells.
___ expression is high in cells, resulting in immortality.
___ transporters are high in stem cells, giving them drug resistance.
Proliferation rates are low in stem cells, giving them what?
Resistance to drugs that act selectively on cells progressing through the cell cycle
Cancer stem cells can arise from non-stem cancer cells through ___ and ___ changes.
Cancer stem cells require ___ and ___ signaling proteins from itself or the microenvironment.
TGFbeta and Wnt signaling induce ___ transcription factors that generate the stem cell phenotype.
Cancers become more ___ as they progress. Cancers come from a cancer ___ cell.
Driver mutations occur rarely in a background of long-lived ___ of cells that continually accumulate passenger mutations without gaining a growth advantage.
A small population of cancer stem cells many maintain many tumors. Describe this process.
A normal stem call and renew itself and produce transit amplifying cells. These can mutate or undergo epigenetic changes that cause acquisition of stem cell properties. Further mutations and epigenetic changes (of both the normal stem cell and the mutated transit amplifying cell) can lead to malignant cancer stem cells. These can self-renew and continue to grow, leading to a tumor.
An epigenetic ___ prevents early tumor progression. Describe this process.
Gatekeeper; silencing of genes such as p16 in stem and precursor cells may lock cells into stem cell-like states that foster abnormal clonal expansion. Their normal epigenetic expression allows them to be activated during stem/precursor cell differentiation as needed to control adult cell renewal.
What are the three major types of epigenetic changes associated with cancer progression? All of these changes lead to ___.
DNA methylation, histone modification, chromatin remodeling; gene silencing
Promoter ___ leads to gene silencing, as does histone modifications promoting transcription ___.
Binding of the Polycomb repressive complex 2 (PRC2) to ___ leads to inhibition of transcription, chromatin compaction, and recruitment of DNA methyltransferase.
Various loss and gain of function mutations in ___ component genes can lead to cancer.
Translocations lead to activation of a proto-oncogene or loss of a tumor suppressor gene in CML. Give an example of this.
Philadelphia chromosome - fusion protein known as Bcr-Abl, leads to overactive Abl kinase, which activates the cell cycle.
___ inhibits Bcr-Abl tyrosine kinase. How?
Gleevec; competitively binding in the ATP-binding pocket of Bcr-Abl, blocking phosphorylation and transmission of the signal.